FENNEC PHARMACEUTICALS INC. Cash and Restricted Cash
FENNEC PHARMACEUTICALS INC. (FENC) had Cash and Restricted Cash of $41.25 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.25M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $40.18M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.79M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21.95M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $41.25M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $40.18M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $36.79M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $21.95M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $18.70M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $22.68M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $26.63M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $40.32M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $43.05M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $51.18M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $13.27M 10-K · filed 2026-03-27 |
| 2023-09-30 | $12.40M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $14.96M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $18.39M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $23.77M 10-K · filed 2025-03-26 |
| 2022-09-30 | $29.75M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $14.91M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $18.26M 10-Q · filed 2023-05-12 |
| 2021-12-31 | $21.10M 10-K · filed 2024-03-29 |
| 2021-09-30 | $24.34M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $27.29M 10-Q · filed 2022-08-12 |
| 2021-03-31 | $26.75M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $30.34M 10-K · filed 2023-03-29 |
| 2019-12-31 | $13.65M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |